367 related articles for article (PubMed ID: 18953554)
21. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
22. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
25. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
26. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
27. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
Chen WL; Chen YM; Chu HS; Lin CT; Chow LP; Chen CT; Hu FR
PLoS One; 2014; 9(4):e94205. PubMed ID: 24714670
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
30. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
31. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
32. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG
Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219
[TBL] [Abstract][Full Text] [Related]
33. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
Qian CX; Bahar I; Levinger E; Rootman D
Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
[TBL] [Abstract][Full Text] [Related]
34. Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.
Kim YC; Grossniklaus HE; Edelhauser HF; Prausnitz MR
Invest Ophthalmol Vis Sci; 2014 Sep; 55(11):7376-86. PubMed ID: 25212779
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
You IC; Kang IS; Lee SH; Yoon KC
Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
[TBL] [Abstract][Full Text] [Related]
36. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
37. Subconjunctival bevacizumab for vascularized rejected corneal grafts.
Awadein A
J Cataract Refract Surg; 2007 Nov; 33(11):1991-3. PubMed ID: 17964413
[TBL] [Abstract][Full Text] [Related]
38. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
39. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
[TBL] [Abstract][Full Text] [Related]
40. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
